ClinicalTrials.gg
Not yet recruitingNCT07833475Updated Oct 13, 2026

The Immediate Effects of Dry Needling Acupuncture on Pain Intensity and Pressure Pain Threshold in Patients With Myofascial Pain Syndrome of the Upper Trapezius

An interventional study of Dry Needling Acupuncture in Myofascial Pain Syndrome, sponsored by Universitas Indonesia. Not yet recruiting at 1 site in Indonesia. Open to participants aged 18 Years to 59 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Universitas Indonesia · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 59 Years
Sex
All
01

Study summary

This study aims to evaluate the immediate effects of a single session of dry needling on pain intensity and pressure pain threshold in patients with myofascial pain syndrome of the upper trapezius muscle. Outcomes will be assessed using the Numeric Rating Scale (NRS) and Pressure Pain Threshold (PPT) at baseline and at 30 minutes, 24 hours, and 72 hours after treatment.

Read the detailed description

Myofascial pain syndrome (MPS) is a regional pain condition involving muscles, fascia, and surrounding soft tissues and is commonly associated with myofascial trigger points (MTrPs). The upper trapezius muscle is a frequent site of MTrPs and may be associated with neck and shoulder pain, muscle stiffness, and functional limitations.

Dry needling is a minimally invasive acupuncture technique that uses a sterile filiform needle without the administration of pharmacological substances. The needle is inserted into the identified myofascial trigger point with the aim of providing mechanical stimulation and inducing a local twitch response. These effects may contribute to the reduction of MTrP irritability and pain through mechanical and neurophysiological mechanisms.

This study is designed as a quasi-experimental study using a one-group pretest-posttest design. The study will be conducted at the Medical Acupuncture Clinic of RSUPN Persahabatan, Jakarta, from August to December 2026. The study will include adult participants aged 18-59 years with posterior neck and shoulder pain, a myofascial trigger point in the upper trapezius muscle, a baseline Numeric Rating Scale (NRS) score of 4-6, and a Pressure Pain Threshold (PPT) of ≤3 kg.

Eligible participants who provide written informed consent will undergo a single session of dry needling. The intervention will be performed by a medical acupuncture resident of the Faculty of Medicine, Universitas Indonesia, with competency level 3. A sterile acupuncture needle measuring 0.25 × 40 mm will be inserted into the identified myofascial trigger point of the upper trapezius muscle at a 90-degree angle to the skin surface in the superior-inferior direction. Fast-in and fast-out needle manipulation will be performed for a maximum of three times or until one local twitch response occurs. The needle will then be immediately removed without retention.

Pain intensity and pressure pain threshold will be assessed immediately before the intervention and at 30 minutes, 24 hours, and 72 hours after the intervention. Pain intensity will be measured using the Numeric Rating Scale (NRS), ranging from 0 to 10, with higher scores indicating greater pain intensity. Pressure pain threshold will be measured using an algometer at the identified anatomical site, and the value will be recorded at the point when the participant first reports a sensation of pain.

The primary outcomes of interest are changes in NRS and PPT from baseline following the dry needling intervention. The study will evaluate changes at 30 minutes, 24 hours, and 72 hours after treatment.

Participants will also be monitored for adverse effects associated with the procedure. Following the intervention, participants will receive instructions regarding post-procedure care, including avoiding massage of the treated area and heavy shoulder loading, performing stretching exercises, maintaining ergonomic posture, and using a cold compress if discomfort occurs.

Data will be analyzed using SPSS version 25.0. Numerical variables will be assessed for normality using the Shapiro-Wilk test. For normally distributed paired data, the paired t-test will be used, while the Wilcoxon signed-rank test will be used for non-normally distributed data. Statistical significance will be defined as p \< 0.05.

02

Conditions studied

  • Myofascial Pain Syndrome
03

In context

Myofascial Pain Syndromes

339 studies on the registry are indexed under Myofascial Pain Syndromes; 66 are open to participants now.

This study's planned enrollment of 30 is below the median of 50 across 307 interventional studies indexed under Myofascial Pain Syndromes.

Browse Myofascial Pain Syndromes studies →

Lead sponsor

Universitas Indonesia is the lead sponsor of 35 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 59 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants aged 18-59 years with complaints of pain in the posterior neck and shoulder regions.
  • Myofascial trigger points (MTrPs) identified on palpation of the upper trapezius muscle.
  • Numeric Rating Scale (NRS) score of 4-6 and Pressure Pain Threshold (PPT) ≤ 3 kg
  • Willingness to participate in the study until completion and to sign the form.

Exclusion criteria

Exclusion Criteria:

  • A previous diagnosis of cervical herniated nucleus pulposus (HNP).
  • History of thread-embedding acupuncture therapy in the upper trapezius muscle within the past 6 months.
  • History of dry needling (DN) and/or acupuncture therapy in the upper trapezius muscle within the past 1 week.
  • History of taking analgesic and anti-inflammatory medications within the past 24 hours.
  • Presence of a tumor, wound, or skin infection at the needling site.
  • History of reactions to previous acupuncture therapy (metal allergy, severe atopy, keloids, or other skin hypersensitivity).
  • Presence of a blood disorder or use of anticoagulant medications (heparin and warfarin).
  • Pregnant women.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Intervention

    Dry Needling Acupuncture

    Device: Dry Needling Acupuncture

Interventions

  • DeviceDry Needling Acupuncture

    The procedures will be done once, and outcomes will be evaluated at 30 minutes, 24 hours, and 72 hours after treatment.

06

What researchers measure

Primary outcomes

  1. Pain Intensity Measured by the Numeric Rating Scale (NRS)

    The Numeric Rating Scale (NRS) measures self-reported pain intensity. The NRS is an 11-point numerical scale ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. Participants select the number that best represents their pain intensity at the time of assessment. Higher scores indicate greater pain intensity. The outcome is the change in NRS pain intensity from baseline to immediately after the dry needling intervention.

    Time frame: baseline, 30 minutes, 24 hours, and 72 hours after treatment

  2. Change in Pressure Pain Threshold (PPT) of the Upper Trapezius Muscle

    Pressure Pain Threshold (PPT) is an objective measure of pressure pain sensitivity in deep muscular tissue. PPT is defined as the minimum amount of externally applied pressure at which a gradually increasing, non-painful pressure stimulus is first perceived as painful. PPT will be measured using a pressure algometer applied to the specified measurement point in the upper trapezius muscle. The pressure will be increased gradually until the participant reports the onset of pain. The pressure value at the onset of pain will be recorded. Higher PPT values indicate lower pressure pain sensitivity, whereas lower PPT values indicate greater pressure pain sensitivity. The outcome measure is the change in PPT from baseline to immediately after the dry needling intervention.

    Time frame: baseline, 30 minutes, 24 hours, and 72 hours after treatment

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers and description
1 update, last Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Minor edits only
    + 2 other changes: identifiers and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07833475
Lead sponsor
Universitas Indonesia
Responsible party
Meitty Marisha (MD, Universitas Indonesia) — Principal investigator
First posted
Sep 22, 2026
Start date
Sep 30, 2026 (estimated)
Primary completion
Oct 3, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Oct 13, 2026

Study contacts

Meitty Marisha, MD
Contact
meitty.marisha@ui.ac.id
08561812511
Medical Acupuncture Study Program FKUI
principal investigator · Medical Acupuncture Study Program Faculty of Medicine Universitas Indonesia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion